天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Pharmaceutical intermediates>Bulk Drug Intermediates>Ibrutinib
Ibrutinib
  • Ibrutinib

Ibrutinib NEW

Price Get Latest Price
Package 1kg 10kg 100kg
Min. Order: 1kg
Supply Ability: 20tons
Update Time: 2023-08-04

Product Details

Product Name: Ibrutinib CAS No.: 936563-96-1
Min. Order: 1kg Purity: 99%
Supply Ability: 20tons Release date: 2023/08/04

Elutinib property Melting point 153-158 ° C Boiling point 715.0 ± 60.0 ° C (Predicted) Density 1.34 Storage condition -20 ° C Solubility SolubleinDMSO (uptoatleast25mg/ml) Acid dissociation constant (pKa) 4.09 ± 0.30 (Predicted) Morphology Solid color Whiteoroff white stability Stablefor1yearfromdateofpurchaseasupplied.SolutionsinDMSOmayrestoredat-20 ° Cforupto3months.InChIKeyXYFPWWZEPKGCCK-GOSISDBHSA-NSMI LESC (N1CCC [C @ @ H] (N2C3C (C (C4=CC=C (OC5=CC=CC=C5)) C=C4)=N2)=C (N) N=CN=3) C1) (=O) C=CCAS database 936563-96-1 Usage and synthesis method of Irutinib Irutinib is a Bruton Tyrosine kinase (BTK) inhibitor, which is used to treat Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non Hodgkin lymphoma, which is difficult to cure and easy to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Irutinib can target BTK, which is essential for the formation, differentiation, information transmission, and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibiting the proliferation and survival of tumor cells; After oral administration, the absorption is rapid, reaching the maximum blood drug concentration within 1-2 hours. The adverse reactions belong to level 1 or 2, and will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the US Food and Drug Administration (FDA) accelerated the approval of Pharmacyclics and Johnson&Johnson's Imbruvica (commonly known as Ibrutinib) for the treatment of a rare invasive blood cancer - mantle cell lymphoma (MCL). Ibrutinib is an oral first new drug of Bruton Tyrosine kinase (BTK) inhibitor. It was granted the drug qualification of breakthrough Sex therapy by FDA in February 2013, and was approved as a therapeutic drug for MCL and CLL on November 13, 2013 and February 12, 2014, respectively. The drug selectively covalently binds to the cysteine residue (Cys-481) at the Active site of the target protein Btk, and Irreversible process inhibits BTK, thus effectively preventing the tumor from migrating from B Cell migration to the lymphoid tissue adapted to the tumor growth environment. The above information was edited and organized by Xiaonan from Chemicalbook.

Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
$10.00/1kg
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
2024-11-21
$36.00/5mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$0.00/10g
VIP3Y
HangZhou RunYan Pharma Technology Co.,LTD.
2024-09-20
$0.00/1g
VIP1Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-07-24
$1.00/1g
VIP1Y
Apeloa production Co.,Limited
2024-06-17
$30.00/1kg
VIP1Y
hebei hongtan Biotechnology Co., Ltd
2024-05-17
$0.00/1kg
VIP1Y
Shaanxi TNJONE Pharmaceutical Co., Ltd
2024-04-12
$1.00/1g
VIP4Y
Dorne Chemical Technology co. LTD
2024-03-26
$0.10/1kg
VIP2Y
Zibo Hangyu Biotechnology Development Co., Ltd
2024-02-04
$0.00/1kg
VIP1Y
Shandong Hanjiang Chemical Co., Ltd
2024-01-22

XuZhou Magic Biotechnology Co., Ltd.

3YR ChinaChina
  • Since: 2021-11-10
  • Address: ?No.016, fengwang Road, Wanggou Town, Fengxian, Xuzhou City
INQUIRY